Long-Acting Beta-Blockers (Beta Antagonists)
The long-acting beta-blockers proven effective in clinical practice include metoprolol succinate, carvedilol, bisoprolol, and nebivolol 1.
Specific Long-Acting Beta-Blockers
These four agents are specifically recommended for long-term management based on mortality reduction data:
- Metoprolol succinate (not metoprolol tartrate) - β1-selective, long-acting formulation
- Carvedilol - nonselective β-blocker with additional α-blocking properties; may be particularly beneficial due to more favorable glycemic control
- Bisoprolol - longer-acting β1-selective agent that demonstrated 32% reduction in all-cause mortality
- Nebivolol - β1-selective with vasodilating properties through nitric oxide modulation
Key Clinical Distinctions
Formulation matters critically: Metoprolol succinate (the long-acting formulation) showed superior outcomes compared to metoprolol tartrate. The COMET trial demonstrated carvedilol had 17% greater mortality reduction compared to metoprolol tartrate 1.
Additional Long-Acting Agents
Other long-acting beta-blockers mentioned in the literature include:
- Propranolol LA (long-acting) - nonselective β-blocker with sustained-release formulation that showed superior 24-hour blood pressure control compared to sustained-action metoprolol 2
- Bopindolol - nonselective β-blocker developed as a pro-drug with 50-60 times more potent long-acting hypotensive effects than atenolol or propranolol 3
Important Caveats
Avoid atenolol: Despite being commonly used, atenolol showed inferior outcomes in two major RCTs (LIFE and ASCOT) and has untoward metabolic effects similar to nonselective beta-blockers 4.
Selectivity considerations: β1-selective agents (bisoprolol, metoprolol succinate, nebivolol) are preferred in patients with bronchospastic disease, while nonselective agents or those with low β1-selectivity may worsen classical pulmonary asthma 4.